- Home
- TEN vs EYPT Comparison
TEN vs EYPT Comparison
Compare TEN & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEN
- EYPT
- Stock Information
- Founded
- TEN 1993
- EYPT 1987
- Country
- TEN Greece
- EYPT United States
- Employees
- TEN N/A
- EYPT N/A
- Industry
- TEN
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- TEN
- EYPT Industrials
- Exchange
- TEN NYSE
- EYPT Nasdaq
- Market Cap
- TEN 531.7M
- EYPT 594.5M
- IPO Year
- TEN N/A
- EYPT 2005
- Fundamental
- Price
- TEN $16.91
- EYPT $7.89
- Analyst Decision
- TEN Buy
- EYPT Strong Buy
- Analyst Count
- TEN 2
- EYPT 8
- Target Price
- TEN $31.00
- EYPT $27.29
- AVG Volume (30 Days)
- TEN 430.9K
- EYPT 918.1K
- Earning Date
- TEN 11-26-2024
- EYPT 11-07-2024
- Dividend Yield
- TEN 11.03%
- EYPT N/A
- EPS Growth
- TEN N/A
- EYPT N/A
- EPS
- TEN 5.46
- EYPT N/A
- Revenue
- TEN $836,042,000.00
- EYPT $45,713,000.00
- Revenue This Year
- TEN N/A
- EYPT N/A
- Revenue Next Year
- TEN $10.35
- EYPT N/A
- P/E Ratio
- TEN $3.02
- EYPT N/A
- Revenue Growth
- TEN N/A
- EYPT 7.50
- 52 Week Low
- TEN $15.88
- EYPT $7.21
- 52 Week High
- TEN $31.48
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- TEN 26.60
- EYPT 41.68
- Support Level
- TEN $15.88
- EYPT $7.21
- Resistance Level
- TEN $19.16
- EYPT $8.21
- Average True Range (ATR)
- TEN 0.64
- EYPT 0.49
- MACD
- TEN -0.06
- EYPT -0.02
- Stochastic Oscillator
- TEN 24.39
- EYPT 42.82
About TEN TSAKOS ENERGY NAVIGATION
Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.